Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A digital health platform for assisting the diagnosis and monitoring of COVID-19 progression: An adjuvant approach for augmenting the antiviral response and mitigating the immune-mediated target organ damage.
Ishay Y, Potruch A, Schwartz A, Berg M, Jamil K, Agus S, Ilan Y. Ishay Y, et al. Among authors: agus s. Biomed Pharmacother. 2021 Nov;143:112228. doi: 10.1016/j.biopha.2021.112228. Epub 2021 Sep 22. Biomed Pharmacother. 2021. PMID: 34649354 Free PMC article.
Improving the response to lenvatinib in partial responders using a Constrained-Disorder-Principle-based second-generation artificial intelligence-therapeutic regimen: a proof-of-concept open-labeled clinical trial.
Sigawi T, Gelman R, Maimon O, Yossef A, Hemed N, Agus S, Berg M, Ilan Y, Popovtzer A. Sigawi T, et al. Among authors: agus s. Front Oncol. 2024 Jul 30;14:1426426. doi: 10.3389/fonc.2024.1426426. eCollection 2024. Front Oncol. 2024. PMID: 39139285 Free PMC article.
Difficult Diagnosis and Management of Concealed Cushing.
Salcuni AS, Marchese F, Cellini M, Brunetti A, Kara E, Manso J, Tonelli V, Cipri C, Carpentieri M, Sciannimanico SM, Galasso S, Agus S, Vescini F. Salcuni AS, et al. Among authors: agus s. Endocr Metab Immune Disord Drug Targets. 2024 May 20. doi: 10.2174/0118715303322153240513103529. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2024. PMID: 38778592
Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trial.
Lobo SM, Plantefève G, Nair G, Joaquim Cavalcante A, Franzin de Moraes N, Nunes E, Barnum O, Berdun Stadnik CM, Lima MP, Lins M, Hajjar LA, Lipinski C, Islam S, Ramos F, Simon T, Martinot JB, Guimard T, Desclaux A, Lioger B, Neuenschwander FC, DeSouza Paolino B, Amin A, Acosta SA, Dilling DF, Cartagena E, Snyder B, Devaud E, Barreto Berselli Marinho AK, Tanni S, Milhomem Beato PM, De Wit S, Selvan V, Gray J, Fernandez R, Pourcher V, Maddox L, Kay R, Azbekyan A, Chabane M, Tourette C, Esmeraldino LE, Dilda PJ, Lafont R, Mariani J, Camelo S, Rabut S, Agus S, Veillet S, Dioh W, van Maanen R, Morelot-Panzini C. Lobo SM, et al. Among authors: agus s. EClinicalMedicine. 2024 Jan 3;68:102383. doi: 10.1016/j.eclinm.2023.102383. eCollection 2024 Feb. EClinicalMedicine. 2024. PMID: 38545090 Free PMC article.
43 results